Drugs / Zovaglutide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07697846 | Jul 2026 → Jan 2027 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07443059 | Apr → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07230119 | Mar 2026 → May 2027 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zovaglutide | “Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.” NCT07697846 ↗ |
| Known as | ZT002 Injection | “Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.” NCT07697846 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC), Q4W” NCT07230119 ↗ |